Global Biosimilar Market Outlook 2018 -




Published: February 2014 | Pages: 145


 
The global biosimilars market is at a crucial turning point, as biosimilars are gaining wide acceptance around the world, with regulatory pathways being clearly defined in every region and R&D investments being at an all time high. Several biosimilars have entered the market over the past 2-3 years. In 2008, Merck, one of the big pharma manufacturers, embraced biosimilars. Large scale partnerships to develop biosimilars are also being announced such as those between Samsung and Biogen, Amgen and Watson, Dr. Reddy’s and Merck Serano.

 
According to our latest research report, “Global Biosimilar Market Outlook 2018”, although the current biosimilars market is small, the future looks optimistic with number of innovative biologics going off patent. Our report discusses major trends and drivers in detail and the influence they will have on the market. Emerging markets will play the role of a major driver for the biosimilars market, which will be attributed to the local policies and the biosimilar attitude of the regions. The governments in the emerging economies are encouraging the growth of biosimilars by defining clear regulatory pathways.

 
In our report, we have segmented the biosimilars market into various categories such as EPO (Erythropoietin), HGH (Human Growth Hormone), IFN (Interferon), mAb (Monoclonal Antibody), Insulin and G-CSF (Granulocyte Colony Stimulating Factor). Each market has been analyzed in terms of major approved biosimilars, drug pipeline, and the impact of patent expirations of important biologics.

 
Similarly, major geographies are also discussed. Apart from the most regulated market of Europe, other economies such as US, India, China and Korea have been discussed. The regulatory scenario of all the economies has been presented. India, for example, recently announced its much awaited new and simple regulatory guidelines, “Guidelines on Similar Biologics”.

 
At the end, major players based in key economies have been profiled. A brief business overview of these players is given along with approved biosimilar products and the ones in the pipeline. Other than the regular players, the past few years have witnessed the entry of major pharma players into the biosimilars scenario. The strong biosimilar pipelines of these players need to be monitored carefully as they have the potential to change the whole scenario within the near future. Overall, the report will provide a good understanding of the market and the recent trends that are prevailing in it.

 
1. Analyst View
2. Research Methodology
3. Biologics Market Outlook to 2018
     3.1 Market Size
     3.2 Market Segmentation
4. Market Trends & Drivers
     4.1 Emerging Markets to Play a Pivotal Role in the Growth of Biosimilars
     4.2 Rising Business Alliances Aiding in Biosimilar Development
     4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth
5. Biosimilars Market Outlook to 2018
     5.1 Market Size
     5.2 Market Segmentation
            5.2.1 Erythropoietin
                       5.2.1.1 Scientific Insight
                       5.2.1.2 Market Analysis
                       5.2.1.3 Recent Activities
            5.2.2 Human Growth Hormone
                       5.2.2.1 Scientific Insight
                       5.2.2.2 Market Analysis
                       5.2.2.3 Recent Activities
            5.2.3 G-CSF
                       5.2.3.1 Scientific Insight
                       5.2.3.2 Market Analysis
                       5.2.3.3 Recent Activities
            5.2.4 Monoclonal Antibody
                       5.2.4.1 Scientific Insight
                       5.2.4.2 Market Analysis
                       5.2.4.3 Recent Activities
            5.2.5 Human Insulin
                       5.2.5.1 Scientific Insight
                       5.2.5.2 Market Analysis
                       5.2.5.3 Recent Activities
            5.2.6 Interferons
                       5.2.6.1 Scientific Insight
                       5.2.6.2 Market Analysis
6. Major Geographical Market
     6.1 US
            6.1.1 Market Analysis
            6.1.2 Regulatory Analysis
            6.1.3 Recent Activities
     6.2 Europe
            6.2.1 Market Analysis
            6.2.2 Regulatory Analysis
            6.2.3 Recent Activities
     6.3 India
            6.3.1 Market Analysis
            6.3.2 Regulatory Analysis
            6.3.3 Recent Activities
     6.4 China
            6.4.1 Market Analysis
            6.4.2 Regulatory Analysis
            6.4.3 Recent Activities
     6.5 Korea
            6.5.1 Market Analysis
            6.5.2 Regulatory Analysis
            6.5.3 Recent Activities
7. Competitive Landscape (Key Products & Recent Activities)
     7.1 US
            7.1.1 Hospira
     7.2 Europe
            7.2.1 Stada Arzneimittel
            7.2.2 Hexal AG
            7.2.3 Ratiopharm GmbH
            7.2.4 Sandoz GmbH
            7.2.5 Bioton
     7.3 India
            7.3.1 Dr.Reddy's Labs (DRL)
            7.3.2 Intas Pharmaceuticals Ltd.
            7.3.3 Biocon Limited
            7.3.4 Wockhardt Limited
            7.3.5 Shantha Biotechnics Limited
            7.3.6 Reliance Life Sciences
     7.4 China
            7.4.1 3 SBio Inc.
     7.5 Korea
            7.5.1 LG Life Sciences
            7.5.2 Celltrion Pharm Inc.
            7.5.3 Dong-A Pharmaceutical Co., Ltd
     7.6 Others
            7.6.1 Teva

 
List of Figures:

 
Figure 3-1: Global - Biologics Market (Billion US$), 2013-2018
Figure 3-2: Global - Biologics Market by Segment (%), 2013
Figure 5-1: Global - Biosimilars Market (Million US$), 2013 & 2018
Figure 5-2: Global - Biosimilars Market by Key Segment (%), 2013
Figure 5-3: Global - Biosimilars Market by Key Segment (%), 2018
Figure 5-4: Global - Erythropoietin Biosimilars Market (Million US$), 2013 & 2018
Figure 5-5: Global - HGH Biosimilars Market (Million US$), 2013 & 2018
Figure 5-6: Global - G-CSF Biosimilars Market (Million US$), 2013 & 2018
Figure 5-7: Global - mAb Biosimilars Market (Million US$), 2013 & 2018
Figure 5-8: Global - Insulin Biosimilars Market (Million US$), 2013 & 2018
Figure 5-9: Global - Interferon Biosimilars Market (Million US$), 2013 & 2018

 
List of Tables:

 
Table 5-1: Global Biosimilar Market - Key Players by Rank
Table 5-2: Global - Biosimilar EPOs Approved for Marketing
Table 5-3: Global Biosimilar EPO Market - Key Players by Rank
Table 5-4: Global - Biosimilar EPOs in Pipeline
Table 5-5: Global - Patent Expiry Status of EPOs
Table 5-6: Global - Biosimilar HGH Approved for Marketing
Table 5-7: Global Biosimilar HGH Market - Key Players by Rank
Table 5-8: Global - Biosimilar HGH in Pipeline
Table 5-9: Global - Biosimilar G-CSF Approved for Marketing
Table 5-10: Global Biosimilar G-CSF Market - Key Players by Rank
Table 5-11: Global - Biosimilar G-CSF in Pipeline
Table 5-12: Global - Patent Expiry Status of G-CSF
Table 5-13: Global - Biosimilar mAbs Approved for Marketing
Table 5-14: Global Biosimilar mAb Market - Key Players by Rank
Table 5-15: Global - Biosimilar mAbs in Pipeline
Table 5-16: Global - Patent Expiry Status of mAbs
Table 5-17: Global - Biosimilar Insulin Approved for Marketing
Table 5-18: Global Biosimilar Insulin Market - Key Players by Rank
Table 5-19: Global - Biosimilar Insulin in Pipeline
Table 5-20: Global - Patent Expiry Status of Insulin
Table 5-21: Global - Biosimilar Interferons Approved for Marketing
Table 5-22: Global - Biosimilar Interferons in Pipeline
Table 5-23: Global - Patent Expiry Status of Interferons
Table 6-1: Biosimilars of US-based Companies Approved for Marketing
Table 6-2: Biosimilars of US-based Companies in Pipeline
Table 6-3: US - Patent Expiry Status of Biologics
Table 6-4: Biosimilars of European Companies Approved for Marketing
Table 6-5: Biosimilars of European Companies in Pipeline
Table 6-6: Europe - Patent Expiry Status of Biologics
Table 6-7: Biosimilars of Indian Companies Approved for Marketing
Table 6-8: Biosimilars of Indian Companies in Pipeline
Table 6-9: Biosimilars of Chinese Companies Approved for Marketing
Table 6-10: Biosimilars of Chinese Companies in Pipeline
Table 6-11: Biosimilars of Korean Companies Approved for Marketing
Table 6-12: Biosimilars of Korean Companies in Pipeline
Table 6-13: Korea - Patent Expiry Status of Biologics